HB3834 creates the “Oklahoma Breakthrough Therapy Act” and directs the State Department of Health to contract, if funding is available, with a drug developer to support multistate clinical trials of ibogaine and ibogaine-based therapeutics. The bill is aimed at obtaining U.S. Food and Drug Administration approval for ibogaine through sanctioned trials, and it requires the developer to present a detailed trial strategy, participant protocols, evidence of existing multistate collaboration, and financial disclosures before a contract can be approved.
The bill also sets out the terms the state must negotiate in any contract, including a requirement that the developer match the state’s investment with equal additional funding, conduct the trials in Oklahoma to the maximum extent possible, and provide quarterly progress and financial reports. It further requires a plan for post-approval access to ibogaine in Oklahoma, including priority access for residents, payer coverage efforts, access for uninsured and low-income patients, and training and credentialing of providers. The bill recognizes a state economic interest in intellectual property and related rights arising from the trials and directs any state share of proceeds into a new Ibogaine Development Revolving Fund.
In terms of state law impact, the bill adds new provisions to Title 63 governing health department contracting, reporting, and fund creation. It establishes the Ibogaine Development Revolving Fund as a continuing, non-lapsing fund that may receive appropriations, donations, grants, and intellectual-property proceeds, and it authorizes spending for programs or research benefiting at-risk populations with conditions potentially treatable with ibogaine, including traumatic brain injury, opioid use disorder, co-occurring substance use disorder, and certain neurological or mental health disorders. It also provides that Oklahoma-licensed medical professionals cannot be disciplined solely for recommending participation in ibogaine clinical trials.
The overall sentiment reflected in the voting history appears generally favorable but not unanimous. The bill advanced with strong support in House and Senate committees and passed both chambers, though it drew meaningful opposition on floor votes, indicating that while many lawmakers supported exploring ibogaine as a potential treatment pathway, a substantial minority remained skeptical or concerned about the policy.
The main points of contention likely center on the use of state funds for a drug still seeking FDA approval, the risks and ethics of clinical trials involving ibogaine, and the state’s role in negotiating intellectual property and commercialization rights. Supporters appear focused on innovation, treatment access, and potential benefits for opioid use disorder and other serious conditions, while opponents likely questioned safety, fiscal exposure, and whether the state should be involved in advancing a controversial therapy.
HB3834 amends Oklahoma law by creating new statutory sections in Title 63 that authorize the State Department of Health to enter into a specialized contract for ibogaine clinical trials, establish reporting requirements, and create the Ibogaine Development Revolving Fund. It affects the Department of Health, drug developers engaged in multistate research, licensed medical professionals, and future patients who may seek ibogaine treatment if approved. The bill also creates a state claim to a proportional share of intellectual-property and commercialization proceeds tied to the trials.
The bill appears to have broad but not universal support. It passed committee stages with little resistance and cleared both chambers, but the floor votes in the House and Senate show a notable bloc of opposition. That pattern suggests lawmakers were generally receptive to the idea of supporting ibogaine research and potential treatment access, while some remained unconvinced about the safety, cost, or appropriateness of state involvement.
The likely areas of disagreement are the use of public money for a substance that is not yet FDA-approved, the medical and regulatory risks associated with ibogaine, and the state’s participation in negotiating intellectual-property rights from the research. Supporters likely emphasize innovation, treatment for opioid use disorder and related conditions, and economic upside for Oklahoma, while critics likely focus on fiscal prudence, patient safety, and whether the state should be endorsing or facilitating a controversial therapy.